Management of active tuberculosis

American Family Physician

Volumn 72, Issue 11, 2005, Pages 2225-2232

  Potter, Beth ^a,c   Rindfleisch, Kirsten ^a   Kraus, Connie K ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Wisconsin Medical School ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BCG VACCINE; CAPREOMYCIN; CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ANTIBIOTIC THERAPY; BACTERIUM DETECTION; BCG VACCINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COUGHING; DISEASE ACTIVITY; DRUG DOSE REGIMEN; EXTRAPULMONARY TUBERCULOSIS; FETUS DISEASE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; MALAISE; REVIEW; SPUTUM CULTURE; SPUTUM SMEAR; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TOXIC HEPATITIS; TREATMENT INDICATION; TUBERCULOSIS; UNITED STATES; WEIGHT REDUCTION;

ALGORITHMS; ANTITUBERCULAR AGENTS; HUMANS; RECURRENCE; RISK FACTORS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 28744450943     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Accessed online July 25, 2005, at: http://www.who.int/docstore/gtb/publications/ttgnp/PDF/2003.313.pdf.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
3. Institute of Medicine, Committee on the Elimination of Tuberculosis in the United States. Ending neglect: the elimination of tuberculosis in the United States. Washington, D.C.: National Academy Press, 2000.
4. National Center for HIV, STD, and TB Prevention, Division of Tuberculosis Elimination. Reported tuberculosis in the United States, 2002. Atlanta: U.S. Department of Health and Human Services, 2003.
5. Office of Disease Prevention and Health Promotion. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Washington, D.C.: U.S. Department of Health and Human Services, 1996.
6. Ozuah PO, Ozuah TP, Stein RE, Burton W, Mulvihill M. Evaluation of a risk assessment questionnaire used to target tuberculin skin testing in children. JAMA 2001;285:451-3.
7. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996;45(RR-4):1-18.
8. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887-99.
9. American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161(4 pt 1):1376-95.
10. Catanzaro A, Perry S, Clarridge JE, Dunbar S, Goodnight-White S, LoBue PA, et al. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial [published correction appears in JAMA 2000;284:1663]. JAMA 2000;283:639-45.
11. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis [published correction appears in MMWR Recomm Rep 2005;53:1203]. MMWR Recomm Rep 2003;52:1-77. Accessed online September 14, 2005, at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/rr5211a1.htm.
12. Centers for Disease Control and Prevention. Notice to readers: updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2004;53:37. Accessed online September 14, 2005, at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm.
13. Smego RA, Ahmed N. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int J Tuberc Lung Dis 2003;7:208-13.